Treatment of allergic rhinitis using a combination of mometasone and olopatadine
The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
1. A method of treating one or more symptoms associated with allergic rhinitis in a human subject in need thereof comprising nasally administering twice daily, two sprays per nostril of a fixed-dose pharmaceutical composition comprising mometasone furoate and olopatadine hydrochloride, wherein (i) each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride, and (ii) the administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 15 minutes of administration.
2. The method of claim 1 , wherein the symptoms to be treated are selected from nasal symptoms and non-nasal symptoms.
3. The method of claim 1 , wherein the symptoms to be treated are selected from nasal symptoms.
4. The method of claim 3 , wherein the nasal symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.
5. The method of claim 1 , wherein the human subject is at least 12 years of age.
6. The method of claim 1 , wherein the allergic rhinitis is selected from seasonal allergic rhinitis, perennial allergic rhinitis, and persistent allergic rhinitis.
7. The method of claim 6 , wherein the allergic rhinitis is seasonal allergic rhinitis.
8. The method of claim 6 , wherein the allergic rhinitis is perennial allergic rhinitis.
9. A method of treating a human subject suffering from one or more symptoms of allergic rhinitis comprising the step of administering to the subject a pharmaceutical composition for twice daily nasal administration of two sprays per nostril, wherein (i) the pharmaceutical composition provides an onset of action within 15 minutes for the treatment of one or more symptoms of allergic rhinitis and (ii) each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride.
10. The method of claim 1 , wherein the human subject is at least 12 years of age.
11. The method of claim 1 , wherein the allergic rhinitis is seasonal allergic rhinitis.
12. The method of claim 1 , wherein the allergic rhinitis is perennial allergic rhinitis.
13. The method of claim 7 , wherein the human subject is at least 12 years of age.
14. The method of claim 11 , wherein the human subject is at least 12 years of age.
15. The method of claim 7 , wherein the symptoms to be treated are selected from nasal symptoms.
16. The method of claim 15 , wherein the nasal symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.
17. The method of claim 9 , wherein the symptoms to be treated are selected from nasal symptoms.
18. The method of claim 17 , wherein the nasal symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.
19. The method of claim 11 , wherein the symptoms to be treated are selected from nasal symptoms.
20. The method of claim 19 , wherein the nasal symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.
21. The method of claim 1 , wherein the administration of the pharmaceutical composition provides relief from nasal symptoms associated with allergic rhinitis within 15 minutes of administration.
22. The method of claim 7 , wherein the administration of the pharmaceutical composition provides relief from the nasal symptoms associated with seasonal allergic rhinitis within 15 minutes of administration.
23. The method of claim 9 , wherein the administration of the pharmaceutical composition provides relief from the nasal symptoms associated with allergic rhinitis within 15 minutes of administration.
24. The method of claim 11 , wherein the administration of the pharmaceutical composition provides relief from the nasal symptoms associated with seasonal allergic rhinitis within 15 minutes of administration.